Rexahn Pharma's Archexin has received FDA orphan drug designation for RCC, glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.
Drug data expected early 2015
"Archexin is a potential best-in-class, potent inhibitor of the protein kinase phosphorylated Akt-1, which is over expressed in cancer cells and which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance."
Comments
vlad.adrian
⋅
I recommend you watch Boiler Room and The Wolf of Wall Street, maybe then your dreams of easy money will vanish.
Y2C
⋅
I've seen both and understand the pump and dumps... Are you familiar with biotech companies and their potential? If not I recommend you look at these charts (2-5yr frame) and then maybe you'll thank me for sharing my idea.
ACAD
PCYC
ITMN
ICPT
ALKS
ALNY
PCRX
There are more but those are a few bios that looked small once upon a time, and look at them now :)
Y2C
⋅
If there is one real way to make easy money right now it's in the biotech sector... Just look at the IBB and XBI and compare it to any other index in the market over the last 3 years.
I guess it's important to mention the sector is very speculative and very volatile, but great for active aggressive and risk tolerant swing traders
Y2C
⋅
If there is one real way to make easy money right now it's in the biotech sector... Just look at the IBB and XBI and compare it to any other index in the market over the last 3 years.
I guess it's important to mention the sector is very speculative and very volatile, but great for active aggressive and risk tolerant swing traders
vlad.adrian
⋅
Having a long on IBB is not the same thing as having a long on a penny bio stock